ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,777.01
0.10%
Dow Jones
44,546.08
0.00%
Gold vs US Dollar
2,915.88
0.57%
Brent Oil
74.90
-0.31%
Bitcoin
96,209.57
0.45%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
18/02/202513:00UK RegulatoryTiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
18/02/202513:00UK RegulatoryFDH Aero Names Ian Walsh as Chief Executive Officer
18/02/202513:00UK RegulatoryBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsBIT:1BIIBBiogen Inc
18/02/202513:00UK RegulatoryPetosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinomaTG:2GHMerus NV
18/02/202513:00UK RegulatoryTaseko to Release Fourth Quarter and Year End 2024 ResultsTSXV:TKOTaseko Mines Limited
18/02/202513:00UK RegulatoryBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsTG:IDPBiogen Inc
18/02/202513:00UK RegulatoryTaseko to Release Fourth Quarter and Year End 2024 ResultsLSE:TKOTaseko Mines Limited
18/02/202513:00UK RegulatoryBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsLSE:0R1BBiogen Inc
18/02/202513:00UK RegulatoryWillScot Broadens Capital Allocation by Initiating Cash Dividend ProgramLSE:0A1NWillscot Corp
18/02/202513:00UK RegulatoryTaseko to Release Fourth Quarter and Year End 2024 ResultsTG:UDMTaseko Mines Ltd
18/02/202513:00UK RegulatoryBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsXE:IDPBiogen Inc
18/02/202512:59PR Newswire (US)ZERO Prostate Cancer Launches Bold $20 Million 'Blitz The Barriers' Initiative to Close Gaps in Prostate Cancer Survival in Highest-Risk Communities
18/02/202512:59PR Newswire (US)Lab0 Emerges from Stealth Mode to Unveil Industrial Humanoid-Inspired System for Automated Warehouse Operations
18/02/202512:58PR Newswire (US)GC376, the Primary Component of Anivive's Feline Infectious Peritonitis Drug, Nominated by AVMA and FelineVMA to FDA's List of Bulk Drug Substance for Compounding Office Stock
18/02/202512:58PR Newswire (US)Cronometer Enhances Health Tracking with Seamless Integration of Continuous Glucose Monitors
18/02/202512:55Alliance NewsAlliance NewsEXTRA: May rate cut seen as jobs market holds up better than forecast
18/02/202512:53PR Newswire (US)Yiren Digital Integrates DeepSeek to Boost Innovation and Operational ExcellenceNYSE:YRDYiren Digital Ltd
18/02/202512:53UK RegulatoryTemple Bar Investment Trust Plc - Net Asset Value(s)LSE:TMPLTemple Bar Investment Trust Plc
18/02/202512:51PR Newswire (US)SpyAssociates.com Launches New MEFF M2-PRO TSCM 24GHz AI Spectrum Analyzer: Revolutionizing Counter Surveillance
18/02/202512:49UK RegulatoryNotification of major holdingsLSE:RWIRenewi Plc
18/02/202512:49UK RegulatoryNotification of major holdingsTG:1K5ARenewi Plc
18/02/202512:49UK RegulatoryNotification of major holdingsEU:RWIRenewi Plc
18/02/202512:49PR Newswire (US)Record 20th anniversary year results solidify DIFC's position as region's number one global financial centre
18/02/202512:45UK RegulatoryForm 8.3 - [THRUVISION GROUP PLC- 17 02 2025] - (CGAML)
18/02/202512:45PR Newswire (US)Magaya Releases AI-Powered Customs Filing Solution
18/02/202512:44UK RegulatoryMIGO Opportunities Trust plc - Net Asset Value(s)LSE:MIGOMigo Opportunities Trust Plc
18/02/202512:41UK RegulatoryForm 8.3 - [LEARNING TECHNOLOGIES GROUP PLC - 17 02 2025] - (CGWL)
18/02/202512:41PR Newswire (US)Flourish Research Announces Strategic Acquisition of Diablo Clinical Research
18/02/202512:41PR Newswire (US)Record 20th anniversary year results solidify DIFC's position as region's number one global financial centre
18/02/202512:38UK RegulatoryForm 8.3 - [ALLIANCE PHARMA PLC - 17 02 2025] - (CGWL)

Your Recent History

BIT
UB8VQV
Unicredit Bank
BIT
S28277
Societe Generale Effekten
BIT
UC7PSD
Unicredit Bank
BIT
UB7DJZ
Unicredit Bank
TSXV
SKE
Skeena Resources
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads